Characterisation of a Live-Attenuated Rabies Virus Expressing a Secreted scFv for the Treatment of Rabies.
PEP
antibody
lyssavirus
rabies
rabies treatment
scFv
virus attenuation
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
31 07 2023
31 07 2023
Historique:
received:
07
07
2023
revised:
27
07
2023
accepted:
28
07
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Rabies virus (RABV) causes possibly the oldest disease and is responsible for an estimated >59,000 human fatalities/year. Post exposure prophylaxis (PEP), the administration of vaccine and rabies immunoglobulin, is a highly effective tool which is frequently unavailable in RABV endemic areas. Furthermore, due to the constraints of the blood-brain barrier, current PEP regimes are ineffective after the onset of clinical symptoms which invariably result in death. To circumvent this barrier, a live-attenuated recombinant RABV expressing a highly RABV-neutralising scFv antibody (62-71-3) linked to the fluorescent marker mCherry was designed. Once rescued, the resulting construct (named RABV-62scFv) was grown to high titres, its growth and cellular dissemination kinetics characterised, and the functionality of the recombinant 62-71-3 scFv assessed. Encouraging scFv production and subsequent virus neutralisation results demonstrate the potential for development of a therapeutic live-attenuated virus-based post-infection treatment (PIT) for RABV infection.
Identifiants
pubmed: 37632016
pii: v15081674
doi: 10.3390/v15081674
pmc: PMC10458464
pii:
doi:
Substances chimiques
Rabies Vaccines
0
Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
PLoS Negl Trop Dis. 2009 Nov 03;3(11):e542
pubmed: 19888334
J Virol. 2005 Dec;79(24):15405-16
pubmed: 16306612
Avicenna J Med Biotechnol. 2010 Jan;2(1):3-21
pubmed: 23407587
EMBO Mol Med. 2020 Nov 6;12(11):e12628
pubmed: 32945125
J Immunol. 2006 Jun 15;176(12):7666-75
pubmed: 16751414
Vet Med (Auckl). 2015 Nov 05;6:361-371
pubmed: 30101121
J Immunol. 2015 Nov 1;195(9):4358-68
pubmed: 26408670
J Gen Virol. 2018 Feb;99(2):169-180
pubmed: 29300155
FEBS Lett. 2004 Mar 12;561(1-3):132-6
pubmed: 15013764
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120142
pubmed: 23798690
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11300-5
pubmed: 19581599
Curr Protoc Microbiol. 2020 Jun;57(1):ecpmc105
pubmed: 32475066
J Virol. 2002 Apr;76(7):3374-81
pubmed: 11884563
PLoS One. 2011;6(9):e25414
pubmed: 21980450
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7252-6
pubmed: 1496020
Viruses. 2021 Jan 06;13(1):
pubmed: 33419096
Int J Infect Dis. 2010 Dec;14(12):e1067-71
pubmed: 20947403
PLoS One. 2018 Nov 7;13(11):e0207009
pubmed: 30403742
J Biomed Sci. 2012 Jun 26;19:61
pubmed: 22734518
PLoS Negl Trop Dis. 2013 Sep 19;7(9):e2375
pubmed: 24069466
Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16328-32
pubmed: 15520387
Methods Mol Biol. 2020;2097:253-263
pubmed: 31776931
J Virol. 2020 Mar 17;94(7):
pubmed: 31969432
Fluids Barriers CNS. 2013 Nov 22;10(1):33
pubmed: 24262108
J Vis Exp. 2014 Nov 04;(93):e52065
pubmed: 25407402
J Virol. 1998 May;72(5):3711-9
pubmed: 9557653
Plant Biotechnol J. 2017 Oct;15(10):1331-1339
pubmed: 28273388
Antiviral Res. 2017 Jul;143:1-12
pubmed: 28385500
Vaccine. 2005 Jul 14;23(32):4101-9
pubmed: 15964478
Rev Sci Tech. 2018 Aug;37(2):681-689
pubmed: 30747117
J Gen Virol. 2013 Feb;94(Pt 2):284-292
pubmed: 23100360
J Virol. 2008 Mar;82(5):2330-8
pubmed: 18094173
Trop Med Infect Dis. 2017 Aug 09;2(3):
pubmed: 30270894
Virus Res. 2018 Mar 15;248:39-43
pubmed: 29471052
PLoS Negl Trop Dis. 2019 Jan 29;13(1):e0007128
pubmed: 30695032
J Clin Microbiol. 1989 Nov;27(11):2522-8
pubmed: 2681254
Nat Rev Dis Primers. 2017 Nov 30;3:17091
pubmed: 29188797
J Virol. 2000 Aug;74(16):7261-9
pubmed: 10906180
Viruses. 2019 Dec 18;12(1):
pubmed: 31861477
Hum Vaccin. 2011 Mar;7(3):349-56
pubmed: 21358287
Vaccine. 2013 Mar 15;31(12):1553-9
pubmed: 23370150
Sci Rep. 2016 May 17;6:26100
pubmed: 27185466
J Infect Dis. 2014 Jul 15;210(2):200-8
pubmed: 24511101
J Virol. 2016 Aug 26;90(18):8226-37
pubmed: 27384657
PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003709
pubmed: 25881058
Virology. 1990 Apr;175(2):485-99
pubmed: 2139267
Viruses. 2021 Sep 04;13(9):
pubmed: 34578350
Acta Virol. 2015 Jun;59(2):117-24
pubmed: 26104328
J Vis Exp. 2019 Aug 19;(150):
pubmed: 31475964
FASEB J. 2013 May;27(5):2055-65
pubmed: 23371065
J Virol. 2010 Nov;84(22):11841-8
pubmed: 20826698
J Gen Virol. 2019 Aug;100(8):1171-1186
pubmed: 31237530
World J Virol. 2016 May 12;5(2):85-6
pubmed: 27175354
Future Virol. 2011 Mar 1;6(3):387-397
pubmed: 21686076
J Virol. 2007 Aug;81(15):7993-8
pubmed: 17507463
Front Microbiol. 2017 Feb 03;8:120
pubmed: 28217116
Rev Soc Bras Med Trop. 2020 Nov 06;53:e20200352
pubmed: 33174958
Front Cell Dev Biol. 2021 Feb 09;8:632957
pubmed: 33634109
PLoS Negl Trop Dis. 2009 Oct 06;3(10):e535
pubmed: 19806203